


Take a look at the results! These images show the progress of some patients after using VTAMA cream for 12 weeks.
Click on each section of the photo to the right to see specific areas of the body, or click the button below to view all the images.
Appearance in plaques continued to improve over 40 weeks while on intermittent treatment, and plaque-clearing results lasted even when off treatment in the long-term, open-label extension study

Of patients with mild-to-severe psoriasis who joined the long-term study, 58% achieved clear or almost clear skin at least once.

In a 40-week clinical study, VTAMA cream was proven to be safe and well tolerated for long-term use.

Around 83% of patients said they wanted to continue using VTAMA cream after the clinical study.
The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

OFF-TREATMENT EFFECT
In a long-term, open-label clinical study, 73 patients who had clear skin* because of VTAMA cream were able to stop treatment for a median time of up to 4 months before their plaque psoriasis was no longer clear.
*Psoriasis plaques were measured using the Physician Global Assessment (PGA), a scoring system used by your healthcare provider, and clear skin was defined as a PGA score of 0.

A LONG-TERM, WELL-TOLERATED TREATMENT OPTION
VTAMA cream is a steroid-free plaque psoriasis treatment for adults that’s safe for long-term use, as demonstrated in clinical studies over 52 weeks, even on sensitive areas of your skin—like your face and neck, armpits, chest/breasts, groin, and genitals. Do not use VTAMA cream in your eyes, mouth, or vagina.
-
Steroid Free
-
Safe for Regular, Long-term Use
-
Can Be Applied to Affected Sensitive Skin Areas
Eligible commercially insured patients may pay as little as $0.* Commercially insured patients may pay as little as $75.
*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).